Company Profile

• Cell-based therapy company
  • Porcine islet cell injection to treat Type 1 Diabetes
  • Promising early human data
• Patented proprietary technology
  • 19 issued patents, 37 pending; 12 patent families
• Revenue opportunities
  • Corporate partnering
  • Medical products from pigs for therapeutics and biomaterials applications
• Headquarters in Australia, operations in New Zealand
  • U.S.-based management team in New York
  • Traded on Australian Stock Exchange
  • ADRs listed on the OTCQX in U.S.

Download pdf